Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
about
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondGenome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemiaDistinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcomeMYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myelomaLymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features.Lessons from next-generation sequencing analysis in hematological malignancies.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsWaldenström macroglobulinemia: from biology to treatment.MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Disease-specific mutations in mature lymphoid neoplasms: recent advances.Splenic marginal-zone lymphoma: ontogeny and genetics.Ibrutinib for the treatment of Waldenström macroglobulinemia.Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma.Diagnosis and classification of hematologic malignancies on the basis of genetics.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis.Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma.
P2860
Q27027493-7CF27567-9D3B-4553-B735-3D636AE37F54Q30299913-CA68421C-75D8-4E1B-9E14-03D13F0CE0F2Q30459093-4580E844-5886-4A85-A254-34370C2F2379Q33617237-0FECC660-FB7A-4A74-9D31-29430AFD0EE8Q33660823-4A4E763F-2CAC-4A7A-8D48-C6764E664739Q33746746-8471FEE3-2204-4BDF-A30B-8020E7B890CEQ33798887-76EBEA6B-0E00-4EEC-8B9B-556BA4500F8FQ34101118-11D17609-A9AD-4F7D-BC90-1A99643CA5F6Q34435295-6FC8F593-B0E1-40BB-97DB-0E2869930105Q35041614-0AC202DE-4A65-496E-B7F4-6C792707B6F4Q36058393-461DC8B9-3188-4F35-9A35-4E04D506C44EQ36203511-8555CD82-DFC7-43C3-BC4C-F660388170FFQ36533710-36B86F82-37F9-46D7-A0E2-6F7EEE574FEAQ37318677-5FE50145-CCEE-4B52-A450-DB36DB98D3BEQ37621361-0DC00CA0-3E4D-4E76-9F57-C1523862E09AQ38115233-31C02B1B-0534-4DF1-8884-72BF1909DD60Q38123015-40BD6774-DCC2-4EF5-83DC-7AF4CCD11A90Q38125430-21C335C3-F73A-4617-A980-6DEF053156F3Q38129753-F045E937-9998-48A3-BF19-424209B55926Q38150849-03FBE4E7-CE49-48BB-B612-0169F3DC08A2Q38176969-37B4AAEA-90E9-4F13-9CAF-6C449E9E1A54Q38191449-D9565168-4DEB-4547-B14E-C8F3C134419FQ38199534-BBBF0878-F94D-4299-8259-DCFEBD3F24DFQ38201143-A41A001F-28E8-48A1-9A6C-BCC889A7EA1AQ38209575-3AF8466D-37C9-4998-9B80-DD2A039C5974Q38542260-CF17619F-E90E-4F39-88F7-5F517B033485Q38571471-3C7F685F-30CC-401D-8A2E-49B8925F9E75Q38747789-B987F888-5BD2-4E14-9F8C-5B3594817539Q38760522-BD3C9E3E-4867-47CD-8BBF-2ACB55B02F5FQ38839148-9358B91C-8819-49F6-B5AC-70CC9CA799B6Q38970612-A27F0294-C380-431B-A98C-1981FC85CD71Q39178864-D7164861-1241-45ED-AC4E-575605DF470EQ39363409-E09FCBDF-8DB7-47BC-9138-B1509D72C2C6Q39375290-A12E0A90-BE93-4CC6-93C8-6A7D1EC0D980Q39406673-9258A324-4F90-43AA-AFC7-B5C7A6549B5EQ40954949-FC2F37D0-68B5-477C-A7AC-2F52BCEACD13Q41374007-DFDAC531-84B8-40C7-8BB3-1E1DEC261507Q41521972-A56D9FD0-FA86-4B73-819A-40978D0FE6CEQ42223732-7AA3A84D-328A-4862-A882-7F1B50826F3BQ42371562-9A9061D0-B722-4763-8505-ADEAF221200F
P2860
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Prevalence and clinical signif ...... nd related lymphoid neoplasms.
@en
Prevalence and clinical significance of the MYD88
@nl
type
label
Prevalence and clinical signif ...... nd related lymphoid neoplasms.
@en
Prevalence and clinical significance of the MYD88
@nl
prefLabel
Prevalence and clinical signif ...... nd related lymphoid neoplasms.
@en
Prevalence and clinical significance of the MYD88
@nl
P2093
P1433
P1476
Prevalence and clinical signif ...... nd related lymphoid neoplasms.
@en
P2093
Alessandro Corso
Cristiana Pascutto
Emanuela Boveri
Ester Orlandi
Giorgio Croci
Lucia Morello
Manuel Gotti
Marco Paulli
Maria Luisa Guerrera
Mario Cazzola
P304
P356
10.1182/BLOOD-2012-09-457101
P407
P50
P577
2013-01-25T00:00:00Z